NASDAQ:GMDA - Gamida Cell Stock Price, Forecast & News

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell Ltd (NASDAQ:GMDA) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.07. View Gamida Cell's Earnings History.

Gamida Cell is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Gamida Cell.

Gamida Cell will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 Wall Street analysts have issued 1-year price objectives for Gamida Cell's stock. Their forecasts range from $16.00 to $19.00. On average, they expect Gamida Cell's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 271.9% from the stock's current price. View Analyst Price Targets for Gamida Cell.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.

Media headlines about GMDA stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gamida Cell earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Gamida Cell.

Gamida Cell saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,100 shares, a decline of 8.3% from the January 15th total of 1,200 shares. Based on an average daily volume of 34,800 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold. View Gamida Cell's Current Options Chain.

Some companies that are related to Gamida Cell include Scholar Rock (SRRK), Autolus Therapeutics (AUTL), Adaptimmune Therapeutics (ADAP), Precision BioSciences (DTIL), BioCryst Pharmaceuticals (BCRX), Cabaletta Bio (CABA), PDL BioPharma (PDLI), Gritstone Oncology (GRTS), Harpoon Therapeutics (HARP), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), Novavax (NVAX) and ADMA Biologics (ADMA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Palatin Technologies (PTN), Cisco Systems (CSCO), LYFT (LYFT), Outlook Therapeutics (OTLK), People's United Financial (PBCT), PhaseBio Pharmaceuticals (PHAS), Spring Bank Pharmaceuticals (SBPH), ONEOK (OKE), AcelRx Pharmaceuticals (ACRX) and Antares Pharma (ATRS).

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell's stock is owned by a number of of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (0.69%) and UBS Group AG (0.03%).

GMDA stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..

GMDA stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG.

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GMDA stock can currently be purchased for approximately $4.75.

Gamida Cell has a market capitalization of $115.05 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.

The official website for Gamida Cell is http://www.gamida-cell.com/.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]